Codexis, Inc

About Codexis, Inc

Codexis is a leading protein engineering company applying innovative technologies to Unlock the Power of ProteinsTM. We work collaboratively with our clients to advance protein optimization and production, enabling breakthrough developments in pharmaceuticals and fine chemicals, biotherapeutics, food & beverage, agriculture and other industries.



 

  • US
  • 2015
    On CPhI since
Contact info

Products from Codexis, Inc

  • Codexis® Enzyme Platforms

    Product Codexis® Enzyme Platforms

    Codexis offers biocatalysis products which includes Codexis® enzyme platforms. It includes a variety of enzyme classes, including but not limited to Ketoreductases (KRED), Amine Transaminases (ATA), Nitrilases (NIT), Ene Reductases (ERED) and Halohydrin Dehalogenases (HHDH). All enzymes have been engineered for enhanced selectivity, activity, substrate range and solvent and temperature stability.

    Please contact us for more details!
  • Codex® Amine Transaminase Screening Kit

    Product Codex® Amine Transaminase Screening Kit

    The Codex® ATA Screening Kit contains 24 w-transaminase enzymes (ATAs) that have been selected for their broad substrate range and diverse stereoselectivity for the synthesis of chiral amines from the corresponding ketone and amine donor. This kit is a useful tool to quickly determine the feasibility of using an ATA for an asymmetric transamination. The enzymes included in this kit were developed using Codexis’ CodeEvolver® directed evolution technology platform and have been engineered for enhanced selectivity, activity, substrate range, and solvent and temperature stability.



  • Codex® Ketoreductase Screening Kit

    Product Codex® Ketoreductase Screening Kit

    The Codex® KRED Screening Kit contains 24 ketoreductases (KREDs) that have been selected for their broad substrate range, high and diverse enantioselectivity, and high stability cumulated from more than 70 screening projects. This kit is a useful tool to quickly determine the feasibility of using a KRED for an asymmetric ketone reduction.

    Codexis KREDs have been engineered for enhanced selectivity, activity, substrate range, and solvent and temperature stability. Most of them are tolerant to high concentrations of isopropanol (IPA) and can use IPA as a substrate. This is advantageous as using IPA as a co-solvent will assist in dissolving compounds with poor water solubility and the IPA can act as a substrate for the recycling of NAD(P)H cofactor as shown in the scheme above. The reaction equilibrium is driven to product by using high concentrations of IPA relative to the substrate and/or stripping off the acetone product.



Codexis, Inc Resources

  • News Codexis and Takeda collaborate to advance novel gene therapies

    Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.
  • News Codexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks

    Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, on Tuesday secured a federal court order awarding it summary judgment on 10 claims of patent infringement it brought in a lawsuit against Suzhou, China-based EnzymeWorks, Inc. and its San Diego-based affiliate, also called EnzymeWorks, Inc. The court’s order establishes EnzymeWorks’ uncontested infringement of 10 of Codexis’ patents and eliminates any need for a trial on those issues. The 10 Codexis patents cover dozens of engineered enzymes that have wide industrial applicability.
  • News Codexis Signs Second Multi-Year Agreement in Food Industry with Tate & Lyle

    Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the signing of a multi-year development agreement with Tate & Lyle, a global provider of food ingredients and solutions.  This is the second multi-year agreement signed in recent months between Codexis and Tate & Lyle and highlights Codexis’ continued growth applying its CodeEvolver® protein engineering platform technology in the food industry.  This agreement strengthens the existing partnership between the two companies following the completion of a separate supply agreement in December 2016.
  • News Codexis to Offer High-Performance Enzymes for Diagnostics Markets

    Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will offer high-performance enzymes for customers using next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in vitro molecular diagnostic applications.  Codexis’ first proprietary enzyme for this market will target improved library preparation for NGS users, and is expected to be available in beta-test format by the second quarter of 2017.
  • News Codexis to Commercially Supply Proprietary Enzyme to Tate & Lyle

    Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, today announced that it has entered into an exclusive agreement with Tate & Lyle, a global provider of ingredients and solutions, to supply a proprietary enzyme for use in the company’s food ingredient production.